This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. The company focuses on diseases affecting the back of the eye or retina.View ALIM key stats
Alimera Sciences Inc - ALIM - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Alimera Sciences Inc as a
Sell with a ratings score of D-.
Report Snippet: We rate Alimera Sciences Inc (ALIM) a Sell.
This is based on the convergence of positive investment measures, which should help this stock outperform the majority
of stocks that we rate. The company's strengths can be seen in multiple areas, such as its solid stock price performance,
growth in earnings per share, revenue growth, notable return on equity and expanding profit margins. Although the company
may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.